DocGo, Inc. (DCGO)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$0.40-0.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Broken: Primary pillar broken — Adjusted EBITDA loss narrows to no worse than $10 million in 2026: FY26 EBITDA guidance mid -$19.5M vs -$10M target.
DocGo aims to grow revenue to about $315 million in 2026. The company plans to cut its adjusted EBITDA loss to $5 million. It has extended its share buyback program, showing confidence. The recent acquisition could help expand services and improve results.
DocGo is still losing money with an adjusted EBITDA loss near $18.7 million in Q1 2026. Revenue growth is slow and earnings remain negative. The company faces regulatory risks from Nasdaq listing compliance. Recent earnings misses show weak execution.
The market expects about 6% revenue growth and continued losses in 2026. Our fair value is $2.76, reflecting the turnaround risks. The stock is cheap versus peers but the market prices in a slow recovery, which we see as uncertain.
Breaks if: Adjusted EBITDA loss exceeds $10 million in 2026
Management aims to reduce adjusted EBITDA losses and achieve profitability by the back half of 2026 despite near-term margin pressures.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on improving revenue and reducing losses. The current thesis is in a watch state, reflecting both recent positive performance and ongoing risks.
The market seems to have priced in a low expectations gap, indicating that investors are aware of the company's challenges. Valuation appears cheap compared to peers, but the fundamentals are still loss-making.
Management is focused on increasing revenue guidance and achieving adjusted EBITDA loss reduction, but recent results show mixed progress. There is a high near-term risk of missing earnings expectations, which could impact sentiment.
The future of DCGO depends on several factors, including the company's ability to meet or exceed guidance and the performance of key sector peers. Additionally, macroeconomic conditions, such as job growth, could influence investor sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company completed its acquisition of Hicuity Health. This acquisition may enhance service offerings and support growth. However, the company cut its full-year adjusted EBITDA outlook. The new guidance shows a larger expected loss than before. Investors are concerned about the increased debt from this acquisition.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Adjusted EBITDA guidance for 2026 worsened from a loss of $5-$10 million in 2026-Q1 to a loss of $17-$22 million in 2026-Q2, reflecting margin pressures from hiring and fuel costs. Management still expects to achieve adjusted EBITDA profitability in the back half of 2026, indicating ongoing focus but mixed near-term delivery.
“Full-year 2026 adjusted EBITDA expected to be ($17-$22) million, compared to prior guidance of ($5-$10) million.”
“Full-year 2026 adjusted EBITDA expected to be ($5-$10) million, unchanged from prior guidance.”
Breaks if: Nasdaq delisting or failure to meet listing requirements
Management is working to regain compliance with Nasdaq minimum bid price requirement within the granted extension period.
Newly stated in 2026-Q2. Management disclosed Nasdaq granted an extension of 180 days to regain compliance with the minimum bid price rule, until January 25, 2027. This regulatory priority is ongoing with no financial impact reported yet.
“Nasdaq granted additional 180 days to regain compliance with minimum bid price requirement, until January 25, 2027.”
Breaks if: Full-year 2026 revenue falls below $300 million
Management has increased and narrowed full-year 2026 revenue guidance based on strong demand and organic growth in core services.
Stated as a priority in 2 of last 2 quarters. Management increased full-year 2026 revenue guidance from $290-$310 million in 2026-Q1 to $300-$315 million, then narrowed it to $305-$310 million in 2026-Q2. This reflects strong demand and organic growth in virtual care and mobile phlebotomy, consistent with management's stated growth focus.
“Full-year 2026 revenue range narrowed to $305-$310 million, compared to prior guidance of $300-$315 million.”
“Full-year 2026 revenue is expected to be $300-$315 million, an increase from prior guidance of $290-$310 million.”
Over the next 1 to 3 years, DCGO's performance will be closely tied to its execution on management priorities and external economic factors. Not investment advice.